News & Events

Learn about what's new with CMC Biologics

Takara Bio Selects AGC Biologics as Manufacturer of Plasmid DNA Intermediate for a Vaccine Against COVID-19 (SARS-CoV-2)


(SEATTLE), May 20, 2020 -- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, has announced its partnership with Takara Bio. The companies will partner in the fight against COVID-19 by collaborating on a prophylaxis DNA vaccine, with AGC Biologics manufacturing the plasmid DNA intermediate for the vaccine.

AGC Biologics to Participate in First-Ever BIO Digital Conference


(SEATTLE), May 14, 2020 -- AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), will be participating in the first-ever BIO Digital event.  BIO International Conference is holding its annual event virtually this year in order to safely connect industry experts amidst the COVID-19 global pandemic. The event, which takes place June 8 - 12, brings together capital, scientific and development expertise that is required to turn promising innovation into successful medicine.

AGC Biologics Partners with Faron Pharmaceuticals to Manufacture Cancer Treatment


AGC Biologics will manufacture novel precision cancer immunotherapy treatment Clevegen

(SEATTLE), May 5, 2020 -- AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has been selected to commercially manufacture the treatment Clevegen for partner Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company. Clevegen is a humanized anti-Clever-1 antibody which targets CLEVER-1 positive tumour associated macrophages (TAMs) and converts these highly immunosuppressive M2 macrophages to immune stimulating M1 macrophages. This unique macrophage-directed immuno-oncology switch may be used alone or in combination with other cancer treatments.

AGC Biologics Manufactures Key Ingredient in Potential COVID-19 Treatment Drug, Leronlimab


The drug, Leronlimab, owned by CytoDyn, containing a special molecule manufactured by AGC Biologics, is showing favorable results in the treatment of severely affected COVID-19 patients.  AGC Biologics stands ready to ramp up manufacturing to meet demand once this drug is FDA approved.

Vancouver biotech company tests COVID-19 treatment

AdaptVac Partners with AGC Biologics to Develop & Produce COVID-19 Vaccine


(SEATTLE), April 23, 2020 -- AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it is partnering with AdaptVac to develop and produce a COVID-19 vaccine. AdaptVac, together with its EU Horizon 2020 sponsored PREVENT-nCoV consortium partners, are developing a SARS-CoV-2 vaccine. The COVID-19 pandemic is still evolving, and AdaptVac’s Virus-Like Particle (VLP) technology could provide a solution to protect against new SARS-CoV-2 infections.

AGC Biologics to Participate in Virtual BIO-Europe Spring


AGC Biologics Sponsors 14th Annual BIO-Europe Spring Conference

AGC Biologics in the news for our work toward COVID-19 treatment


Seattle CBS affiliate KIRO visited our Bothell, Washington headquarters to interview AGC Biologics CEO Patricio Massera and Chief Business Officer Mark Womack about the work we’re doing with partner CytoDyn. CytoDyn scientists discovered that HIV drug leronlimab could potentially work to treat COVID-19. AGC Biologics is producing a key molecule for the drug.

DCAT Week Cancelled, AGC Biologics to Meet Virtually with Industry Leaders


AGC Biologics fosters strong customer partnerships by conducting virtual meetings

AGC Inc. Decides to Launch Voluntary Tender Offer for Shares of Molmed


Tokyo, March 17, 2020 – AGC Inc., (Headquarters: Tokyo; President & CEO: Takuya Shimamura) has decided to launch a voluntary tender offer (“VTO”) to acquire all ordinary shares of Molecular Medicine S.p.A. (“Molmed”) a company with shares listed on the Italian Stock Exchange (Milan) pursuant to article 102, first paragraph, of the Italy Legislative Decree No. 58 of 24 February 1998 and related regulations. Molmed is a clinical stage biotechnology company focused on research, development, manufacturing and clinical validation of gene & cell therapies, and offers GMP services for the development and manufacturing of gene & cell therapies for third parties and/or in partnership at its authorized facilities (“CDMO Services”*1).

AGC Biologics Plasmid Production



Follow Us
Join us on LinkedIn Follow us on Twitter